Hangzhou Aorui Biotechnology
Non-invasive diagnostic products for early cancer screening
About Hangzhou Aorui Biotechnology
Hangzhou Aorui Biotechnology, also known as Oriomics, is a life sciences company founded in 2018 and headquartered in Hangzhou, China. The company specializes in developing in-vitro diagnostic products for the early screening and diagnosis of cancer. It utilizes a non-invasive liquid biopsy approach, combining next-generation sequencing (NGS) and PCR multi-omics technology to analyze biomarkers in bodily fluids.
The firm has successfully developed a product for the early detection of liver cancer and is expanding its pipeline to include diagnostics for other high-incidence cancers such as gastric, breast, bowel, pancreatic, and lung cancer, as well as products for detecting multiple cancers simultaneously. The company's technology aims to provide accurate, non-invasive alternatives to traditional diagnostic methods.
Hangzhou Aorui Biotechnology has secured significant funding to support its research and development efforts. The company has raised a total of $15.7M over two funding rounds. Its first funding round was a Series B on January 7, 2022, for $15.7M. A second Series B round for an undisclosed amount occurred on September 11, 2023, with lead investor Fortune Capital and participation from Tao Capital.
Source: Dealroom company dataNews
Open roles
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| SERIES B✓Equity / VC | Sep 2023 | $14M | $55M | Dachen Caizhi · Tao Capital · Hotgen | ↗ |
| SERIES BEquity / VC | Jan 2022 | $14M | $55M | Hotgen | — |
Growth signals
Latest recorded traffic for Hangzhou Aorui Biotechnology is 50 monthly website visits, down 68.8% over the last three months. Hangzhou Aorui Biotechnology's team grew 0% over the past year.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Hangzhou Aorui Biotechnology in the Hangzhou ecosystem
The Hangzhou Aorui Biotechnology office with the hot startups, most funded companies and investors around it. Hover or tap a pin.
Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series A3 investors entered at this stage
Hotgen- DCDachen Caizhi
Tao Capital
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about Hangzhou Aorui Biotechnology on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Hangzhou Aorui Biotechnology’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.